GPVI as an effective antithrombotic target
Slater, Alexandre Khattak, Sophia Thomas, Mark R
Slater, Alexandre
Khattak, Sophia
Thomas, Mark R
Abstract
Glycoprotein (GP) VI plays a major role in thrombosis but not haemostasis, making it a promising antithrombotic target. The primary role of GPVI on the surface of platelets is a signalling receptor for collagen, which is one of the most potent thrombotic sub-endothelial components that is exposed by atherosclerotic plaque rupture. Inhibition of GPVI has therefore been investigated as a strategy for treatment and prevention of atherothrombosis, such as during stroke and acute coronary syndromes. A range of specific GPVI inhibitors have been characterised and 2 of these inhibitors, glenzocimab and revacept, have completed phase II clinical trials in ischemic stroke. In this review, we summarise mechanisms of GPVI activation and the latest progress of clinically tested GPVI inhibitors, including their mechanisms of action. By focussing on what is known about GPVI activation, we also discuss whether alternate strategies could also be used to target GPVI.
MIDER Authors
Citations
Altmetric:
Date
2024-03-07
Type
Article
Subject
Collections
Citation
Slater A, Khattak S, Thomas MR. GPVI as an effective antithrombotic target. Eur Heart J Cardiovasc Pharmacother. 2024 Mar 7:pvae018. doi: 10.1093/ehjcvp/pvae018. Epub ahead of print.
Journal / Source Title
European Heart Journal - Cardiovascular Pharmacotherapy
DOI
10.1093/ehjcvp/pvae018
PMID
38453424
Publisher
Oxford University Press
Publisher’s URL
https://academic.oup.com/ehjcvp